Evaluation of Hippo Pathway and CD133 in Radiation Resistance in Small-Cell Lung Cancer

Figure 2

Prognostic analysis for MST2, pMST2, and pYAP1 performed on clinical samples. (a) Survival differences among MST2 high and low expression groups in SCLC patients assessed via a Kaplan–Meier approach ( = 0.189). Survival differences between (b) pMST2 high and low expressing groups ( = 0.583), (c) pYAP1 high and low expressing groups ( = 0.853), and (d) pYAP1 high and low expressing groups in SCLC patients with high YAP1 expression ( = 0.012).

(a)

(b)

(c)

(d)